NA · Liraglutide

NCT03010683 trial results

Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

Participants: 60
Status: completed
Completed: 2017-12
Sponsor: University of Athens

As posted on ClinicalTrials.gov (NCT03010683), updated at source Mar 5, 2021. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT03010683 measured first

Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.m/s · Baseline, 3 months, 6 months and 12 months · mean

Measure	Liraglutiden=30	Metforminn=30
Baseline	11.8(2.5)	11.2(3)
3 months	11.6(2.8)	11.5(2.7)
6 months	10.3(3.3)	11(3)
12 months	10.5(1.9)	10.8(2)

Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.percentage of the central pulse pressure · Baseline, 3 months, 6 months, and 12 months. · mean

Measure	Liraglutiden=30	Metforminn=30
Baseline	18(-1 to 31)	14(-9 to 24)
3 months	15.8(-2 to 29)	13.6(-6 to 25)
6 months	13(-2 to 31)	15(-8 to 24)
12 months	13.9(-1 to 32)	15.3(-6 to 24)

Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.micrometers · Baseline, 3 months, 6 months, and 12 months. · mean

Measure	Liraglutiden=30	Metforminn=30
Baseline	2.1(0.29)	2.13(0.3)
3 months	2.07(0.3)	2.15(0.3)
6 months	2.5(0.2)	2.13(0.3)
12 months	2.04(0.2)	2.10(0.3)

Secondary outcomes

What else it measured

Endothelial Glycocalyx and Pulse Wave Velocity.Pearson correlation coefficient (r) · Baseline, 3 months, 6 months, and 12 months. · number

Measure	Liraglutiden=30	Metforminn=30
Baseline	0.39	0.35
3 months	0.36	0.32
6 months	0.32	0.29
12 months	0.44	0.37

The trial

How NCT03010683 was run

Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity. Agonists of Glucagon like peptide - 1 receptors (GLP-1R) used in the treatment of type 2 diabetes mellitus (T2DM). This category includes exenatide and liraglutide. These drugs lower glucose levels by inhibiting the secretion of glucagon, promoting the release of insulin in response to hyperglycemia, slowing gastric emptying, and augmenting satiety. Clinical studies have shown that GLP-1R agonists have beneficial effects on cardiovascular function in both diabetic patients and healthy subjects. The purpose of this study is to investigate in patients with T2DM without coronary artery disease (CAD), patients with T2DM and CAD and obese patients with abnormal oral glucose tolerance test (OGTT), changes in arterial stiffness, endothelial glycocalyx thickness and coronary reserve flow (CFR) after treatment with metformin or agonist GLP-1R.

liraglutide
Metformin

Who could join the trial

Inclusion Criteria: * Patients with type 2 diabetes mellitus (T2DM) without coronary artery disease (CAD) * Patients with T2DM and CAD. * Obese patients (BMI \>30 Kg/m²) with abnormal oral glucose tolerance test (OGTT) Exclusion Criteria: * valvular heart disease * congestive heart failure * peripheral vascular disease * liver or kidney failure * history of alcohol or drug abuse

Published papers

Papers from NCT03010683

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.